Wave of promising study results raise hopes for coronavirus vaccines

COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla

By Administrator_India

Capital Sands

Early data from trials of three potential COVID-19 vaccines released on Monday, including a closely-watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight the novel coronavirus without serious side effects.

Whether any of these efforts will result in a vaccine capable of protecting billions of people and ending the global pandemic that has claimed more than 600,000 lives is still far from clear. All will require much larger studies to prove they can safely prevent infection or serious disease.

The vaccine being developed by British drugmaker AstraZeneca along with the Oxford University, induced an immune response in all study participants who received two doses without any worrisome side effects.

A coronavirus vaccine under development by CanSinoBiologics Inc and China’s military research unit, likewise showed that it appears to be safe and induced an immune response in most of the 508 healthy volunteers who got one dose of the vaccine, researchers reported.

Some 77% of study volunteers experienced side effects like fever or injection site pain, but none considered to be serious.

Both the AstraZeneca and CanSino vaccines use a harmless cold virus known as an adenovirus to carry genetic material from the novel coronavirus into the body. Studies on both vaccines were published in the journal The Lancet.

However, the CanSino candidate again showed signs that people who had previously been exposed to the particular adenovirus in its vaccine had a reduced immune response.

The study authors called that “the biggest obstacle” for the vaccine to overcome.

German biotech BioNTech and U.S. drugmaker Pfizer Inc released details from a small study in Germany of a different type of vaccine that uses ribonucleic acid – a chemical messenger that contains instructions for making proteins.

The vaccine instructs cells to make proteins that mimic the outer surface of the coronavirus. The body recognizes these virus-like proteins as foreign invaders and can then mount an immune response against the actual virus.

In the not-yet peer reviewed study of 60 healthy adults, the vaccine induced virus-neutralizing antibodies in those given two doses, a result in-line with a previous early-stage U.S. trial. The burst of announcements followed publication last week of results of Moderna Inc’s vaccine trial, showing similarly promising early results. Moderna’s vaccine also uses a messenger RNA platform.

Related Posts
India reports 4,194 new COVID-19 cases, 255 deaths from virus in 24 hours
new Covid cases

India reported 4,194 new COVID-19 cases in the last 24 hours taking the total confirmed tally to 4,29,84,261 while active infections continued Read more

ब्रिटेन में 12 साल से कम उम्र के बच्चों को भी लगेगी Covid वैक्सीन, रेगुलेटरी एजेंसी ने दी मंजूरी
कोरोना वायरस (Coronavirus) के नए और अधिक संक्रामक वेरिएंट ओमिक्रॉन (Omicron) के सामने आने के बाद ब्रिटेन में हालात बिगड़ते जा रहे हैं.

कोरोना वायरस (Coronavirus) के नए और अधिक संक्रामक वेरिएंट ओमिक्रॉन (Omicron) के सामने आने के बाद ब्रिटेन में हालात बिगड़ते Read more

COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla
COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla

By Administrator_India Capital Sands Export of COVID-19 vaccines can start in about next two weeks, the Business Standard reported, quoting Serum Read more

Serum, Bharat Biotech vaccines get restricted use approval from DCGI
COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla

By Administrator_India Capital Sands India’s drug regulator on Sunday gave its final approval to the Oxford-AstraZeneca and Bharat Biotech coronavirus vaccines for restricted use Read more

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x